Jack C R, Shiung M M, Gunter J L, O'Brien P C, Weigand S D, Knopman D S, Boeve B F, Ivnik R J, Smith G E, Cha R H, Tangalos E G, Petersen R C
Department of Diagnostic Radiology and MR Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Neurology. 2004 Feb 24;62(4):591-600. doi: 10.1212/01.wnl.0000110315.26026.ef.
To correlate different methods of measuring rates of brain atrophy from serial MRI with corresponding clinical change in normal elderly subjects, patients with mild cognitive impairment (MCI), and patients with probable Alzheimer disease (AD).
One hundred sixty subjects were recruited from the Mayo Clinic Alzheimer's Disease Research Center and Alzheimer's Disease Patient Registry Studies. At baseline, 55 subjects were cognitively normal, 41 met criteria for MCI, and 64 met criteria for AD. Each subject underwent an MRI examination of the brain at the time of the baseline clinical assessment and then again at the time of a follow-up clinical assessment, 1 to 5 years later. The annualized changes in volume of four structures were measured from the serial MRI studies: hippocampus, entorhinal cortex, whole brain, and ventricle. Rates of change on several cognitive tests/rating scales were also assessed. Subjects who were classified as normal or MCI at baseline could either remain stable or convert to a lower-functioning group. AD subjects were dichotomized into slow vs fast progressors.
All four atrophy rates were greater among normal subjects who converted to MCI or AD than among those who remained stable, greater among MCI subjects who converted to AD than among those who remained stable, and greater among fast than slow AD progressors. In general, atrophy on MRI was detected more consistently than decline on specific cognitive tests/rating scales. With one exception, no differences were found among the four MRI rate measures in the strength of the correlation with clinical deterioration at different stages of the disease.
These data support the use of rates of change from serial MRI studies in addition to standard clinical/psychometric measures as surrogate markers of disease progression in AD. Estimated sample sizes required to power a therapeutic trial in MCI were an order of magnitude less for MRI than for change measures based on cognitive tests/rating scales.
将正常老年人、轻度认知障碍(MCI)患者和可能患有阿尔茨海默病(AD)的患者的连续MRI测量脑萎缩率的不同方法与相应的临床变化相关联。
从梅奥诊所阿尔茨海默病研究中心和阿尔茨海默病患者登记研究中招募了160名受试者。基线时,55名受试者认知正常,41名符合MCI标准,64名符合AD标准。每位受试者在基线临床评估时接受脑部MRI检查,1至5年后进行随访临床评估时再次接受检查。从连续MRI研究中测量四个结构的体积年化变化:海马体、内嗅皮质、全脑和脑室。还评估了几种认知测试/评分量表的变化率。基线时被分类为正常或MCI的受试者可能保持稳定或转变为功能较低的组。AD受试者被分为进展缓慢组和进展快速组。
转变为MCI或AD的正常受试者的所有四种萎缩率均高于保持稳定的受试者,转变为AD的MCI受试者的萎缩率高于保持稳定的受试者,进展快速的AD受试者的萎缩率高于进展缓慢的受试者。一般来说,MRI上检测到的萎缩比特定认知测试/评分量表上的下降更一致。除一个例外,在疾病不同阶段与临床恶化的相关性强度方面,四种MRI率测量方法之间未发现差异。
这些数据支持除标准临床/心理测量方法外,使用连续MRI研究的变化率作为AD疾病进展的替代标志物。为MCI治疗试验提供足够效力所需的估计样本量,MRI比基于认知测试/评分量表的变化测量方法少一个数量级。